Incidence of hepatocellular carcinoma (HCC) is on the rise due to the prevalence of chronic
hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues …

Immune associated cells in the microenvironment have a significant impact on the
development and progression of hepatocellular carcinoma (HCC) and have received more …

Endoplasmic reticulum (ER) stress promotes tumor cell escape from immunosurveillance.
However, the underlying mechanisms remain unknown. We hypothesized that ER stress …

abstract Despite significant research efforts, only a few treatment approaches have been
developed for hepatocellular carcinoma (HCC). In recent years, immune checkpoint …

Immunotherapy directed at the PD-L1/PD-1 axis has produced treatment advances in
various human cancers. Unfortunately, progress has not extended to glioblastoma (GBM) …

Treatment options for patients with hepatocellular carcinoma are rapidly changing based on
positive results from phase 3 trials of targeted and immune-based therapies. More agents …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and
confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors …

Mouse models are the basis of preclinical and translational research in hepatocellular
carcinoma (HCC). Multiple methods exist to induce tumour formation in mice, including …

Immunogenic cell death (ICD) can engage a specific immune response and establish a long-
term immunity in hepatocellular carcinoma (HCC). Herein, we design and synthesize a …

Over the last decade, precision medicine and immunotherapeutic approaches have become
increasingly popular in oncology. Early clinical trials reported promising results, but …